DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2021 financial results post-market on November 10, 2021. A conference call is scheduled for November 11, 2021, at 7:00 AM CT to discuss the results and provide a business update. The call can be accessed via telephone or webcast, with a replay available until November 18, 2021. The company focuses on neurological disorders and kidney diseases, with its lead candidate, DM199, aimed at treating acute ischemic stroke and chronic kidney disease.

Positive

• Company will provide Q3 2021 financial results, indicating transparency and communication with investors.
• Lead candidate DM199 addresses significant medical needs in ischemic stroke and chronic kidney disease.

Negative

• None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its third quarter 2021 financial results will be released after the markets close on Wednesday, November 10^th. DiaMedica will host a live conference call on Thursday, November 11^th at 7:00 AM Central Time to discuss its business update and financial results.

Conference Call details:

Date:	Thursday, November 11, 2021
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://events.q4inc.com/attendee/250819405
Dial In:	(888) 440-4368
Conference ID:	4814247

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 18, 2021, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005276/en/

Contact:

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries:

Tim McCarthy

Managing Director, LifeSci Advisors, LLC

tim@lifesciadvisors.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics release its Q3 2021 financial results?

DiaMedica Therapeutics will release its Q3 2021 financial results after the market closes on November 10, 2021.

What time is the DiaMedica conference call scheduled for?

The DiaMedica conference call is scheduled for 7:00 AM CT on November 11, 2021.

How can I access the DiaMedica conference call?

You can access the DiaMedica conference call by dialing (888) 440-4368 or through the webcast at their investor relations page.

What is DM199, DiaMedica's lead candidate?

DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, targeting acute ischemic stroke and chronic kidney disease.